Literature DB >> 7780590

High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.

M T Huizing1, H Rosing, F Koopman, A C Keung, H M Pinedo, J H Beijnen.   

Abstract

A reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for the quantitative determination of paclitaxel in human urine. A comparison is made between solid-phase extraction (SPE) and liquid-liquid extraction (LLE) as sample pretreatment. The HPLC system consists of an APEX octyl analytical column and acetonitrile-methanol-0.2 microM ammonium acetate buffer pH 5 (4:1:5, v/v) as the mobile phase. Detection is performed by UV absorbance measurement at 227 nm. The SPE procedure involves extraction on Cyano Bond Elut columns. n-Butylchloride is the organic extraction fluid used for the LLE. The recoveries of paclitaxel in human urine are 79 and 75% for SPE and LLE, respectively. The accuracy for the LLE and SPE sample pretreatment procedures is 100.4 and 104.9%, respectively, at a 5 micrograms/ml drug concentration. The lower limit of quantitation is 0.01 microgram/ml for SPE and 0.25 microgram/ml for LLE. Stability data of paclitaxel in human urine are also presented.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780590     DOI: 10.1016/0378-4347(94)00477-m

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  6 in total

Review 1.  Environmental monitoring by surface sampling for cytotoxics: a review.

Authors:  Petit Marie; Curti Christophe; Roche Manon; Montana Marc; Bornet Charleric; Vanelle Patrice
Journal:  Environ Monit Assess       Date:  2017-01-06       Impact factor: 2.513

2.  Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

Authors:  Johannes J Moes; Frederik E Stuurman; Jeroen J M A Hendrikx; Serena Marchetti; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens; Bastiaan Nuijen
Journal:  Drug Deliv Transl Res       Date:  2013-06       Impact factor: 4.617

3.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

4.  Effect of supersaturation on the oral bioavailability of paclitaxel/polymer amorphous solid dispersion.

Authors:  Linlin Miao; Yuheng Liang; Wenli Pan; Jingxin Gou; Tian Yin; Yu Zhang; Haibing He; Xing Tang
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

5.  A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.

Authors:  S A Veltkamp; B Thijssen; J S Garrigue; G Lambert; F Lallemand; F Binlich; A D R Huitema; B Nuijen; A Nol; J H Beijnen; J H M Schellens
Journal:  Br J Cancer       Date:  2006-08-22       Impact factor: 7.640

6.  The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Authors:  M M Malingré; J H Schellens; O Van Tellingen; M Ouwehand; H A Bardelmeijer; H Rosing; F J Koopman; M E Schot; W W Ten Bokkel Huinink; J H Beijnen
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.